Recruiting
A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors - CA030-001
Updated: 30 April, 2022 | ClinicalTrials.gov
Print Friendly Summary
Trial Details
Phase
Gender(s)
Age Range
Location(s)
Recruiting
Treatment Options
Inclusion Criteria: - Histologic or cytologic confirmation of a solid tumor that is advanced (metastatic, recurrent, and/or unresectable) with measurable disease or metastatic disease documented by either bone lesions on radionuclide bone scan and/or soft tissue lesions on CT/MRI for prostate cancer and have at least 1 lesion accessible for biopsy. For Part 2B participants with HCC, intermediate disease is allowed. - Eastern Cooperative Oncology Group Performance Status of 0 or 1 - Must have received, and then progressed, relapsed, or been intolerant to, at least 1 standard treatment regimen in the advanced or metastatic setting according to tumor type, if such a therapy exists - Prior anti-cancer treatments such as chemotherapy, radiotherapy, or hormonal are permitted for some participants - Willing and able to comply with all study procedures Exclusion Criteria: - Primary central nervous system (CNS) malignancies, tumors with CNS metastases as the only site of disease or active brain metastases will be excluded - Other active malignancy requiring concurrent intervention - Prior organ allograft - Active, known, or suspected autoimmune disease Other protocol-defined inclusion/exclusion criteria apply
We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information
